CryoLife, Inc. Goodwill and Intangible Assets (Total)

Goodwill and Intangible Assets (Total) of CRY for past 10 years: annual, quarterly and twelve month trailing (TTM) including Goodwill and Intangible Assets (Total) growth rates and interactive chart. The sum of goodwill and all other intangible assets. Intangible assets are items that a company owns and derives benefit from, but is unable to physically measure and count. Examples of intangible assets include patents, trademarks and copyrights. Goodwill is a special type of intangible asset that normally appears in a company's balance sheet following a business combination. When the fair value of the consideration paid by the purchaser for an entity exceeds the fair value of the net assets they have acquired, the purchaser must recognize the resulting difference as goodwill in their balance sheet.


Highlights and Quick Summary

  • Goodwill and Intangible Assets (Total) for the quarter ending March 30, 2021 was $472 Million (a -3.06% decrease compared to previous quarter)
  • Year-over-year quarterly Goodwill and Intangible Assets (Total) increased by 39.63%
  • Annual Goodwill and Intangible Assets (Total) for 2020 was $487 Million (a 41.43% increase from previous year)
  • Annual Goodwill and Intangible Assets (Total) for 2019 was $344 Million (a -1.27% decrease from previous year)
  • Annual Goodwill and Intangible Assets (Total) for 2018 was $349 Million (a -5.13% decrease from previous year)
Visit stockrow.com/CRY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Goodwill and Intangible Assets (Total) of CryoLife, Inc.

Most recent Goodwill and Intangible Assets (Total)of CRY including historical data for past 10 years.

Interactive Chart of Goodwill and Intangible Assets (Total) of CryoLife, Inc.

CryoLife, Inc. Goodwill and Intangible Assets (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $472.19
2020 $487.12 $479.7 $338.17 $336.39 $487.12
2019 $344.43 $342.65 $342.65 $342.52 $344.43
2018 $348.86 $351.56 $357.54 $372.31 $348.86
2017 $367.74 $141.58 $142.68 $143.83 $367.74
2016 $144.94 $144.28 $145.69 $145.01 $144.94
2015 $31.26 $30.52 $31.13 $31.68 $31.26
2014 $32.65 $32.71 $33.15 $33.05 $32.65
2013 $33.28 $33.74 $34.51 $34.96 $33.28
2012 $35.45 $35.86 $36.96 $24.21 $35.45
2011 $24.62 $25.52 $24.84 $8.73 $24.62
2010 $8.88 $8.87 $6.18 $8.88

Business Profile of CryoLife, Inc.

Sector: Healthcare
Industry: Medical Devices
CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.